SUTIMLIMAB-JOME

Other

Brand names: Enjaymo

Intravenous

Mechanism of Action

12.1 Mechanism of Action Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complement pathway (CP) and specifically binds to complement protein component 1, s subcomponent (C1s), a serine protease which cleaves C4. Sutimlimab-jome does not inhibit the lectin and alternative pathways. Inhibition of the classical complement pathway at the level of C1s prevents deposition of complement opsonins on the surface of RBCs, resulting in inhibition of hemolysis in patients with CAD.

Indications

See full prescribing information

FDA Warnings

5 WARNINGS AND PRECAUTIONS Serious Infections: Ensure patients are vaccinated against encapsulated bacteria
2 ) Risk of Autoimmune Disease: Monitor patients for signs and symptoms and manage medically
1 Serious Infections Including Those Caused by Encapsulated Bacteria ENJAYMO, a proximal classical complement C1s inhibitor, increases a patient's susceptibility to serious infections including those caused by encapsulated bacteria e
Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors

Known Side Effects

6 documented side effects by frequency

Joint Pain

1-10%

Condition Worsened

1-10%

Drug Not Working

1-10%

Fatigue

1-10%

Headache

1-10%

Nausea

0.1-1%

Community Discussions

No community discussions found for SUTIMLIMAB-JOME yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous